![Marc Machaalani Profile](https://pbs.twimg.com/profile_images/1709558320191729665/MYQbjGaI_x96.jpg)
Marc Machaalani
@MarcMachaalani
Followers
650
Following
2K
Statuses
2K
Postdoctoral GU Oncology Research Fellow @DanaFarber | MD '23 @LebaneseUni | Classical Pianist
Boston, MA
Joined September 2013
Honored to receive a @ConquerCancerFd Merit Award for our work @ASCO #GU25! Very grateful for the unwavering support of my mentors and colleagues! @DrChoueiri @VincentWenxinXu @ReneeSaliby
11
11
84
RT @srviswanathan: 🚨 New study! 🚨Excited to share our research on #translocationRCC #tRCC published in @NatMetabolism, in collaboration wit…
0
42
0
RT @DrChoueiri: 1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tum…
0
203
0
@WDKhatoun @ConquerCancerFd @ASCO @DrChoueiri @VincentWenxinXu @ReneeSaliby @eddy_saad @Clara__Steiner @yekeduz_emre @maxinesun @DanaFarber_GU @DanaFarberNews Thanks Wassim! Your turn is next
0
0
2
@eddy_saad @yekeduz_emre @ConquerCancerFd @ASCO @DrChoueiri @VincentWenxinXu @ReneeSaliby @Clara__Steiner @maxinesun @DanaFarber_GU @DanaFarberNews Thank you Dr. Saad!
0
0
0
@Clara__Steiner @ASCO @ConquerCancerFd @VincentWenxinXu @DrChoueiri @eddy_saad @ReneeSaliby @marc_eid @KarlSemaan @ShrutiGkidney @DanaFarber_GU Congrats Clara 👏 Proud of you!
0
0
1
RT @Clara__Steiner: Looking forward to attending my 1st @ASCO #GU25 and so grateful to receive a @ConquerCancerFd Merit Award for our work!…
0
4
0
@yekeduz_emre @ConquerCancerFd @ASCO @DrChoueiri @MikeSerzanMD @DrYukselUrun @hatice_bolek @coskunyazgann Congratulations Emre! Well-deserved 👏
0
1
4
RT @yekeduz_emre: 🎉💥🎉Happy to share that our study on merlin-loss RCC has been awarded @ConquerCancerFd "Merit Award" by @ASCO ! 🌟🌟🌟Many…
0
19
0
RT @DrChoueiri: Our translational paper about Natural Killer Cells function (or dysfunction) in RCC in @ESMO_Open ! Take a look @VincentWen…
0
19
0
RT @VincentWenxinXu: 1/8 Our study on natural killer (NK) cell dysfunction in kidney cancer is now out @ESMO_open! Led by co-first authors…
0
22
0